NeuroView completes eight-week canine preclinical implant study

NeuroView completed a canine preclinical trial at the University of Colorado Veterinary School. The NeuroView subgaleal EEG device was implanted in a beagle and monitored for eight weeks to evaluate signal quality, biocompatibility, and safety over eight weeks.

Over the eight-week period the device recorded clean EEG signal with no observed adverse effects. It was explanted in October as planned, at the end of the monitoring protocol.

NeuroView has announced plans for further studies in dogs with naturally occurring epilepsy to evaluate the platform's seizure detection performance and generate additional longitudinal EEG data.